All In Biotech

Drug Trial Radar · NCT04662255

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Apr 8, 2021

Primary completion

Nov 2027

Study completion Jun 2030

Sponsor

Lead sponsor
Loxo Oncology, Inc.Eli Lilly (LLY)
Sponsor type
Industry
Collaborators
Eli Lilly and Company
First posted
Dec 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study for participants with a type of blood cancer called mantle cell lymphoma (MCL). The main purpose is to compare pirtobrutinib (LOXO-305) to other drugs that work in a similar way that have already been approved by the United States Food and Drug Administration (US FDA). Participation could last up to two years, and possibly longer, if the disease does not progress.

Conditions

  • Lymphoma, Mantle-Cell

Interventions

  • PirtobrutinibDrug

    Oral

  • IbrutinibDrug

    Oral

  • AcalabrutinibDrug

    Oral

  • ZanubrutinibDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare progression-free survival (PFS) of pirtobrutinib as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL)Time frame: Up to approximately 24 months

Locations

189 sites in 24 countries. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology, LLC

    Anchorage, Alaska

  • Arizona Oncology Associates, P.C. - HOPE

    Phoenix, Arizona

  • UCLA Medical Center

    Los Angeles, California

  • USO-Rocky Mountain Cancer Center

    Denver, Colorado

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Oncology-Hematology Associates of West Broward

    Tamarac, Florida

  • Florida Cancer Specialists East

    West Palm Beach, Florida

  • University of Kentucky Markey Cancer Center

    Lexington, Kentucky

  • Mercy Health-Paducah Medical Oncology and Hematology

    Paducah, Kentucky

  • Tulane Cancer Center Office of Clinical Research

    New Orleans, Louisiana

  • Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • DFCI Lymphoma

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University Medical School

    St Louis, Missouri

  • Columbia University Medical Center

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Messino Cancer Center

    Asheville, North Carolina

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Wake Forest University School of Medicine

    Winston-Salem, North Carolina

  • Oncology Hematology Care Inc

    Cincinnati, Ohio

  • Willamette Valley Cancer Institute & Research Ctr.

    Eugene, Oregon

  • Sarah Cannon Research Institute SCRI

    Nashville, Tennessee

  • Texas Oncology-Austin Midtown

    Austin, Texas

  • Texas Oncology - Bedford

    Bedford, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology - McAllen

    McAllen, Texas

  • Texas Oncology - Sherman

    Sherman, Texas

  • US Oncology

    The Woodlands, Texas

  • Texas Oncology - Tyler

    Tyler, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • University of Virginia Health System

    Charlottesville, Virginia

  • USO-Virginia Cancer Specialists, PC

    Fairfax, Virginia

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

  • Froedtert Memorial Lutheran Hospital

    Milwaukee, Wisconsin

  • Icon Cancer Care - The Wesley Medical Centre

    Auchenflower, Australia

  • The St. George Hospital

    Kogarah, New South Wales, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

Showing 40 of 189 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.